Sentences with phrase «tumor patient with»

In early clinical trials, Sessler and his colleagues treated 39 metastatic brain tumor patients with texaphyrins 2 hours before radiation therapy for 10 days.

Not exact matches

It will focus its initial clinical sequencing efforts on cancer, teaming up with the Moores Cancer Center at the University of California, San Diego to sequence the genomes of every patient who is treated there, as well as perform a full genome sequence on their tumors.

The indication now covers patients with bone metastases from solid tumors and those with multiple myeloma.

MEG TIRRELL, NIGHTLY BUSINESS REPORT CORRESPONDENT: Since they were approved in 2014, drugs that stimulate the immune system have been giving new hope to patients with melanoma, kidney cancer, lymphoma and other cancers, including famously to President Jimmy Carter, who credited the drug called Keytruda with shrinking tumors that had spread to his brain.

CB - 1158 is being tested in a Phase I clinical trial in patients with solid tumors.»

The targeted radiotherapy shrank tumors for 71 % of patients who had already failed standard chemotherapy, but these results came from a small trial that started with 30 patients and then added another 20 after positive data started rolling in.

Around four - fifths of prostate cancer patients have tumors with lots of PSMA for the therapy to bind to.

Just weeks after he was named chief medical officer at the Roswell Park Cancer Institute, Dr. Boris Kuvshinoff was diagnosed with an inoperable late - stage tumor in the nasal cavity above his mouth and became a patient there.

For example, TCGA, with genomic data on 33 tumor types taken from samples from 11,000 patients, is finishing 2018 by publishing a series of papers and holding a symposium.

Unlike conventional chemotherapies and radiation that indiscriminately eradicate fast - growing tissues and ravage people's bodies with side effects, new therapies specifically target tumors using tailored cells from individual patients.

Finding individual differences in tumors is key to treating the right patient with the right medicine at the right time, researchers say

A patients» tumors from cholangiocarcinoma, a rare liver cancer that typically fails chemotherapy, shrunk significantly after treatment with FGFR inhibitors, which were prescribed based on results of next generation sequencing.

The Moores Cancer Center's Molecular Tumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theraTumor Board brought together medical, surgical and radiation therapy oncologists, biostatisticians, radiologists, pathologists, clinical geneticists, basic and translational science researchers, and bioinformatics and pathway analysis specialists to discuss the intricacies of tumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard theratumor genetics and tailor a personalized treatment plan for patients with advanced cancer or who have exhausted standard therapies.

«These results also provide a rationale to explore the clinical activity of an OX40 agonist antibody in combination with GSK2636771 in cancer patients with PTEN loss tumors.»

In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors showed fewer chromosomal disruptions.

Matching unique genetic information from cancer patients» tumors with treatment options — an emerging area of precision medicine efforts — often fails to identify all patients who may respond to certain therapies.

However, the majority of patients develop treatment - resistant tumors, and only 10 to 15 percent of these patients survive long term, says Ie - Ming Shih, M.D., Ph.D., the Richard W. TeLinde Distinguished Professor in the department of Gynecology and Obstetrics, who led the study with Tian - Li Wang, Ph.D., an associate professor of pathology and oncology at the Johns Hopkins University School of Medicine.

Steven Rosenberg, chief of surgery at NCI, riveted everyone's attention by recounting the varied success of treating patients with tumor - infiltrating lymphocytes and then took a few moments to address audience members about advancing their scientific careers.

Analyzing a database of nearly 800 multiple myeloma patient samples, they discovered that 162 patients with low ADAR1 levels in their tumor cells survived significantly longer over a three - year period compared to 159 patients with high ADAR1 levels.

Seventy four percent of enrolled patients were diagnosed with ovarian cancer with tumors that had relapsed and metastasized in the peritoneum, the membrane that lines the abdominal cavity.

«Particularly in such patients with underlying CKD, our modeling results support the integration of renal tumor anatomic features at cross-sectional imaging into decision making for treatment of small renal masses and may be used to provide a patient - centered framework for selection of optimal candidates for ablative therapy,» Kang said.

The authors suggest that therapies targeting TP53 mutations may yield better clinical outcomes for patients with HPV - inactive tumors.

Led by Stella K. Kang, a radiologist with the Department of Radiology at the New York School of Medicine, the study was designed to compare the effectiveness of a treatment algorithm for small renal tumors incorporating the nephrometry score, a renal tumor anatomy scoring system developed by urologists, with the current standard of uniformly recommended partial nephrectomy in patients with mild - to - moderate chronic kidney disease (CKD).

«We provide a framework for incorporating tumor imaging features and renal function into treatment selection, which may help to inform physicians regarding the appropriateness of surgery in patients with CKD,» Kang said.

«We treated these three patients with drugs that attack these genetic alterations and saw tumor shrinkage.

In a recent study, working with a team of researchers, Danino demonstrated that bacteria in pancreatic tumors degrade a chemotherapy drug — Gemcitabine — most commonly used to treat patients who have pancreatic cancer.

In particular, the study suggests that two miRNAs — miR - 4516 and miR - 601 — in tumor cells along with Gleason score and lymph node status may help identify patients who might experience rising PSA after they've been treated with radiation therapy.

«We now hope to design larger clinical studies to treat patients» tumors harboring these novel genomic aberrations to further explore the precise extent of clinical benefit for patients with primary or advanced cholangiocarcinoma.»

So far, researchers with the Allen Institute for Brain Science in Seattle have described the intricate shapes and electrical properties of about 100 nerve cells, or neurons, taken from the brains of 36 patients as they underwent surgery for conditions such as brain tumors or epilepsy.

Additionally, lung cancer patients who have high levels of YAP1 in their tumors are more likely to have a poorer prognosis than patients with low levels of YAP1.

To uncover how this resistance occurs, Guo and Lu teamed with Xu, Herlyn and colleagues examined both cell lines and tumor biopsies from melanoma patients before and after either BRAF inhibitor therapy or BRAF / MEK inhibitor combination therapy.

They are working together to mesh her identification of compounds that target tumors with runaway Ras activity and tumor data (analyzed by machine learning) to find patients who could benefit from these potential cancer drugs.

«Surgery is the main treatment option for patients with most solid tumors, but recurrence and metastasis remain significant problems,» says study senior author Michael Goldberg, PhD, assistant professor at Dana - Farber and Harvard Medical School.

In many patients diagnosed with LUAD, tumors cells have already spread to the brain, leading to decreased quality of life and low survival rates.

In the context of the collaboration between the Gates Center for Stem Cell Biology and the CU Cancer Center this was the second clinical trial we offered to our patients with the specific intent to eliminate the CSCs in their tumors.»

Researchers used tissue and blood samples to show that the gammopathy (a precursor to myeloma) in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor cells in nearly a third of myeloma patients are directed against such lipids.

To Kalish, the patients who are diagnosed with the syndrome after they develop cancer, like the little girl whose adrenal tumor set off alarm bells, have her wondering whether the incidence of Beckwith - Wiedemann is higher than reported.

To illustrate that point, they analyzed a series of 95 patients with a confirmed diagnosis of brain tumor at their department.

If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»

However, from their experience in treating patients with brain tumors, Dr. Hawasli and coauthors raise concerns about this recommendation.

Eligible patients presented with tumor stages of T1c to T3a, prostate - specific androgen (PSA) levels of 20 or below, and one or two of three risk factors: stage T3a, a Gleason tumor score of seven or higher, or a PSA level greater than 10.

Depending on which set of recent recommendations had been followed, neuroimaging would have been delayed or never performed in three to seven percent of patients with brain tumors.

In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.

The Phase I clinical trial of OMP - 54F28 (FZD8 - Fc) is an open - label dose escalation study in patients with advanced solid tumors for which there was no remaining standard curative therapy.

The Michigan Oncology Sequencing Program (MI - ONCOSEQ) facilitates integrative sequencing analysis of tumors from patients with advanced cancers.

The authors conclude, «Unvalidated guidelines to prevent neuroimaging in patients with headaches may reduce the perceived global economic burden at the expense of medical errors, delayed diagnoses, and inferior outcomes for patients with brain tumor.»

There is currently a PD - 1 antibody on the market that blocks T cell exhaustion in patients with solid tumors, like lung cancer and melanoma.

While there have been improvements in the current standard treatments, patients with glioblastoma (GBM), the most common and aggressive form of brain tumor, still suffer from a median survival rate of only 14.6 months and 5 - year overall survival rates of less than 10 %.

In blood samples from 1005 patients with eight types of tumors that had evidently not yet metastasized, the test detected between 33 % and 98 % of cases, depending on the tumor type (see graph, above).

The IBM Watson Health unit is perhaps the most prominent, with the company for the past several years claiming that its AI is assisting major medical centers and hospitals in tasks such as genetically sequencing brain tumors and matching cancer patients to clinical trials.